Literature DB >> 6520153

Determination of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography.

J Cummings, J F Stuart, K C Calman.   

Abstract

A reversed-phase isocratic high-performance liquid chromatographic assay is described for the measurement of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum. The lower limit of detection in serum is 3 ng/ml for adriamycin and 1 ng/ml for adriamycinol and the 7-deoxyaglycones with coefficients of variation for k' of less than 5% throughout the day. An extraction technique for serum is described which is capable of an almost equal recovery (greater than 77%) of adriamycin, metabolites and daunorubicin (the internal standard) without interference from endogenous components of serum. Serum concentrations of metabolites 15 min after intravenous bolus administration of 40 mg/m2 adriamycin in two different patients were 26.5 and 16.6 ng/ml for adriamycinol; 109.8 and 5.8 ng/ml for the adriamycinol 7-deoxyaglycone and 21.4 and 17.1 ng/ml for the adriamycin 7-deoxyaglycone. A total of six metabolites of adriamycin were detected in the two patients using this methodology.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6520153     DOI: 10.1016/s0378-4347(00)84698-8

Source DB:  PubMed          Journal:  J Chromatogr


  14 in total

1.  Method for the determination of 4-demethoxydaunorubicin, its quinone and hydroquinone metabolites in human plasma and urine by high-performance liquid chromatography.

Authors:  J Cummings; R Milroy; S W Banham; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  The effect of verapamil on the pharmacokinetics of adriamycin.

Authors:  D J Kerr; J Graham; J Cummings; J G Morrison; G G Thompson; M J Brodie; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer.

Authors:  R Milroy; J Cummings; S B Kaye; S W Banham
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 4.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

5.  Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy.

Authors:  S Stallard; J G Morrison; W D George; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20 degrees C and thawing by microwave radiation.

Authors:  L Keusters; L M Stolk; R Umans; P Van Asten
Journal:  Pharm Weekbl Sci       Date:  1986-06-20

7.  Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients.

Authors:  J Cummings; G J Forrest; D Cunningham; N L Gilchrist; M Soukop
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse.

Authors:  I F Uchegbu; J A Double; J A Turton; A T Florence
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

9.  Niosome: A future of targeted drug delivery systems.

Authors:  Karim Masud Kazi; Asim Sattwa Mandal; Nikhil Biswas; Arijit Guha; Sugata Chatterjee; Mamata Behera; Ketousetuo Kuotsu
Journal:  J Adv Pharm Technol Res       Date:  2010-10

10.  N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice.

Authors:  L W Seymour; K Ulbrich; S R Wedge; I C Hume; J Strohalm; R Duncan
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.